上皮细胞黏附分子表达与乳腺癌淋巴结转移的相关性

doi:10.3760/cma.j.issn.1673422X.2017.03.005

摘要/Abstract

摘要： 目的探讨上皮细胞黏附分子（EpCAM）在乳腺癌中的表达及意义。方法收集经病理学确诊的乳腺癌新鲜组织标本23例及配对的淋巴结转移灶。应用同位素标记的相对和绝对定量（iTRAQ）蛋白质组学技术筛选及鉴定乳腺癌原发灶和淋巴结转移灶的差异表达蛋白，在4例新鲜乳腺癌原发灶组织和配对淋巴结转移灶中进行Western blotting检测EpCAM的表达。采用免疫组织化学法检测252例乳腺病变标本中EpCAM的表达。结果定量蛋白质组学检测结果显示乳腺癌原发灶和淋巴结转移灶存在差异表达蛋白，其中EpCAM在转移灶的表达高于原发灶，Western blotting显示EpCAM在转移灶的表达（1.46±0.22）高于原发灶（1.16±0.09），变化趋势与蛋白质组学结果一致。免疫组织化学检测结果显示，EpCAM在淋巴结转移灶中的阳性表达率（93.16%，109/117）显著高于无淋巴结转移的乳腺癌原发灶（72.73%，64/88），差异有统计学意义（χ2=15.921，P=0.000）；有淋巴结转移的乳腺癌原发灶EpCAM阳性表达率为72.65%（85/117），较配对淋巴结转移灶阳性表达率低，差异有统计学意义（P=0.001）。结论EpCAM在乳腺癌原发灶和淋巴结转移灶呈差异表达，该蛋白可能与乳腺癌淋巴结转移有关。

关键词: 细胞黏附分子, 乳腺肿瘤, 蛋白质组学, 免疫组织化学

Abstract: ObjectiveTo investigate the expression and significance of epithelial cell adhesion molecule (EpCAM) in breast cancer. MethodsTwentythree cases of breast cancer tissue samples and paired lymph node metastases confirmed pathologically were collected. Isobaric tags for relative and absolute quantitation (iTRAQ) proteomics technology was used to screen and identify the differentially expressed proteins between primary tumor and lymph node metastasis of breast cancer. The expression of EpCAM was detected by Western blotting in 4 cases of primary breast cancer tissues and paired lymph node metastases. And the expressions of EpCAM in 252 cases of breast lesions were detected by immunohistochemical method. ResultsQuantitative proteomic examination results showed that differentially expressed proteins existed in breast cancer primary tumor and lymph node metastasis, and the expression of EpCAM in metastatic lesions was higher than that in primary tumor. Western blotting results showed that the expression of EpCAM in metastatic lesions (1.46±0.22) was higher than that in primary tumor (1.16±0.09), which was consistent with the results of proteomic. The immunohistochemical results showed that the positive expression rate of EpCAM in lymph node metastasis tissues (93.16%, 109/117) was significantly higher than that in primary breast cancer without metastasis (72.73%, 64/88), and the difference was statistically significant (χ2=15.921, P=0.000). The positive expression rate of EpCAM in primary breast cancer with lymphatic metastasis (72.65%, 85/117) was lower than that in paired lymph node metastases (P=0.001). ConclusionEpCAM is differentially expressed in primary tumor and lymph node metastasis of breast cancer, which may be related to the lymphatic metastasis of breast cancer.

Key words: Cell adhesion molecule, Breast neoplasms, Proteomics, Immunohistochenmistry

张薇薇,钟晶敏,李晶,黄三钱,刘志红,曾亮. 上皮细胞黏附分子表达与乳腺癌淋巴结转移的相关性[J]. 国际肿瘤学杂志, 2017, 44(3): 177-181.

Zhang Weiwei, Zhong Jingmin, Li Jing, Huang Sanqian, Liu Zhihong, Zeng Liang. Correlation of expression of epithelial cell adhesion molecule and lymph node metastasis of breast cancer[J]. Journal of International Oncology, 2017, 44(3): 177-181.

参考文献

［1］ DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013［J］. CA Cancer J Clin, 2014, 64(1): 52-62. DOI: 10.3322/caac.21203. ［2］ Youlden DR, Cramb SM, Yip CH, et al. Incidence and mortality of female breast cancer in the AsiaPacific region［J］. Cancer Biol Med, 2014, 11(2): 101-115. DOI: 10.7497/j.issn.20953941.2014.02.005. ［3］ Sharifian A, Pourhoseingholi MA, Emadedin M, et al. Burden of breast cancer in Iranian women is increasing［J］. Asian Pac J Cancer Prev, 2015, 16(12): 50495052. ［4］ Fry SA, Sinclair J, Timms JF, et al. A targeted glycoproteomic approach identifies cadherin5 as a novel biomarker of metastatic breast cancer［J］. Cancer Lett, 2013, 328(2): 335-344. DOI: 10.1016/j.canlet.2012.10.011. ［5］ Onishi T, Hayashi N, Theriault RL, et al. Future directions of bonetargeted therapy for metastatic breast cancer［J］. Nat Rev Clin Oncol, 2010, 7(11): 641-651. DOI: 10.1038/nrclinonc.2010.134. ［6］ Zeng Q, Zhang P, Wu Z, et al. Quantitative proteomics reveals ERα involvement in CD146induced epithelialmesenchymal transition in breast cancer cells［J］. J Proteomics, 2014, 103: 153-169. DOI: 10.1016/j.jprot.2014.03.033. ［7］ Wilhelm M, Schlegl J, Hahne H. et al. Massspectrometrybased draft of the human proteome［J］. Nature, 2014, 509(7502): 582-587. DOI: 10.1038/nature13319. ［8］ Seviour EG, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phosphoRb signature in breast and ovarian cancer［J］. Oncogene, 2016, 35(6): 801. DOI: 10.1038/onc.2015.177. ［9］ Nagano K. Challenge to the development of molecular targeted therapy against a novel target candidate identified by antibody proteomics technology［J］. Yakugaku Zasshi, 2016, 136(2): 145-149. DOI: 10.1248/yakushi.15002261. ［10］ Bonaldi T, Noberini R. Recent advances in mass spectrometry analysis of histone posttranslational modifications: potential clinical impact of the PATHMS approach［J］. Expert Rev Proteomics, 2016, 13(3): 245-250. DOI: 10.1586/14789450.2016.1147960. ［11］ Gastl G, Spizzo G, Obrist P, et al. EpCAM overexpression in breast cancer as a predictor of survival［J］. Lancet, 2000, 356(9246): 1981-1982. DOI: 10.1016/S01406736(00)033122. ［12］ Ni J，Cozzi PJ，Duan W, et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression［J］. Cancer Metastasis Rev, 2012, 31(34): 779-791. DOI: 10.1007/s1055501293891. ［13］ Zhou N, Wang H, Liu H. MTA1upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer［J］. J Exp Clin Cancer Res, 2015, 34: 157. DOI: 10.1186/s1304601502631. ［14］ Lin Z, Lu X, Li W, et al. Association of cancer stem cell markers with aggressive tumor features in papillary thyroid carcinoma［J］. Cancer Control, 2015, 22(4): 508-514. ［15］ Sung JJ, Noh SJ, Bae JS, et al. Immunohistochemical expression and clinical significance of suggested stem cell markers in hepatocellular carcinoma［J］. J Pathol Transl Med, 2016, 50(1): 52-57. DOI: 10.4132/jptm.2015.10.09. ［16］ Gao J, Liu X, Yang F, et al. By inhibiting Ras/Raf/ERK and MMP9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis［J］. Oncotarget, 2015, 6(29): 27187-27198. DOI: 10.18632/oncotarget.4551. ［17］ Kubisch I, de Albuquerque A, Schuppan D, et al. Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas［J］. Oncology, 2015, 89(5): 294-303. DOI: 10.1159/000437373. ［18］ Mu Y, Sa N, Yu L, et al. Epithelial cell adhesion molecule is overexpressed in hypopharyngeal carcinoma and suppresses the metastasis and proliferation of the disease when downregulated［J］. Oncol Lett, 2014, 8(1): 175-182. DOI: 10.3892/ol.2014.2140. ［19］ Matsuda T, Takeuchi H, Matsuda S, et al. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma［J］. Ann Surg Oncol, 2014, 21 Suppl 3: S356364. DOI: 10.1245/s1043401435798. ［20］ Romeu C, Farré X, Cardesa A, et al. Expression of EpCAM, but not of E48, associates with nodal involvement in advanced squamous cell carcinomas of the larynx［J］. Histopathology, 2013, 62(6): 954-961. DOI: 10.1111/his.12108. ［21］ Takes RP, Baatenburg de Jong RJ, Wijffels K, et al. Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer［J］. J Pathol, 2001, 194(3): 298-302. DOI: 10.1002/10969896(200107)194:3<298::AIDPATH900>3.0.CO;2Q. ［22］ PituchNoworolska A, Drabik G, Szatanek R, et al. Immunophenotype of isolated tumour cells in the blood, bone marrow and lymph nodes of patients with gastric cancer［J］. Pol J Pathol, 2007, 58(2): 93-97.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	廖利华, 王少洪, 陈洪才, 赵勇强. 细胞蜡块免疫组织化学与胸腔积液CRKL、MIC-1诊断恶性胸腔积液的价值[J]. 国际肿瘤学杂志, 2023, 50(2): 71-75.
[14]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[15]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.